Market Research Logo

Global Leukemia Therapeutics Market 2016-2020

Global Leukemia Therapeutics Market 2016-2020

About Leukemia

Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

Technavio’s analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-La Roche
  • Novartis
  • Bristol-Myers Squibb
  • AbbVie
  • Teva Pharmaceuticals
Other prominent vendors
  • Altor BioScience
  • Amgen
  • ARIAD Pharmaceuticals
  • Arno Therapeutics
  • Astex Pharmaceuticals
  • AstraZeneca
  • Baxter Healthcare
  • Bayer HealthCare
  • Bellicum Pharmaceuticals
  • Biogen
  • Boehringer Ingelheim
  • BioLineRx
  • Boston Biomedical
  • Celator Pharmaceuticals
  • Celgene
  • CTI BioPharma
  • Chroma Therapeutics
  • Chugai Pharmaceutical
  • Cyclacel Pharmaceuticals
  • Daiichi Sankyo
  • Eisai
  • Emergent BioSolutions
  • Erytech Pharma
  • Fate Therapeutics
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • iDD biotech
  • Immune Pharmaceuticals
  • Immunomedics
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Jazz Pharmaceuticals
  • Juno Therapeutics
  • Karyopharm Therapeutics
  • Ligand Pharmaceuticals
  • MEDA Pharmaceuticals
  • MedImmune
  • Merck
  • Midas Pharma
  • Molecular Templates
  • MorphoSys
  • Nippon Shinyaku
  • Novo Nordisk
  • Onconova Therapeutics
  • Ono Pharmaceuticals
  • Orphan Europe
  • Otsuka
  • Pfizer
  • Portola Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Sanofi
  • Sigma-Tau Pharmaceuticals
  • Stemline Therapeutics
  • Sunesis Pharmaceuticals
  • TG Therapeutics
  • TheraMAB
  • Tolero Pharmaceuticals
  • XEME Biopharma
  • Xencor
  • ZIOPHARM Oncology
Market driver
  • Technological advances in the monitoring of leukemia
  • For a full, detailed list, view our report
Market challenge
  • Limitations associated with current therapeutic options
  • For a full, detailed list, view our report
Market trend
  • Rise in the development of combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Leukemia Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the leukemia therapeutics market: F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, Teva Pharmaceuticals, Altor BioScience, Amgen, ARIAD Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene, CTI BioPharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, MEDA Pharmaceuticals, MedImmune, Merck, Midas Pharma, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.

Commenting on the report, an analyst from Technavio’s team said: “One of the key trends for market growth will be the rise in the development of combination therapies. Combination therapies for the treatment of leukemia were available only in the form of combination chemotherapy drugs. The some of the approved combinations are chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of CLL; a combination of cytarabine, daunorubicin, and etoposide for the treatment of AML; and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of ALL. Also, it has been observed that vendors are showing more interest in the development of combination therapies to treat various leukemias.”

According to the report, application for expanded indication approvals will be a key driver for market growth. There has been an increase in the R&D activities going on for the re-positioning of already marketed drugs for the new indications in the global leukemia therapeutics market. This concept of re-positioning came into practice in the early 1990s and is originate from the possibility of different diseases could be sharing common molecular pathways. The companies are conducting clinical trials to determine the effectiveness of the drugs in all such related indications. As this process of drug re-positioning leading to extended indication is low risk, high reward strategy, this should increase the scope of treatment and hence, help in the increased market penetration.



Further, the report states that financial and infrastructural constraints will be a major challenge for the market. The financial and infrastructural constraints associated with leukemia medications is high, especially in emerging nations. Most of the branded medications are not available in these regions as the companies have not received approvals. For instance, Venclexta, a product of AbbVie and F. Hoffmann-La Roche, received approval in April 2016 in the US, Europe, and Japan. The drug is yet to be launched in other regions. This reduces the accessibility of drugs for the individuals in these regions. Also, most of the branded therapies are costly. The high cost of therapy is a major factor resulting in treatment withdrawal by individuals. The R&D costs of developing such drugs are usually high. Therefore, manufacturers are forced to pass on these costs to the buyer. However, this inhibits the adoption of the drugs because the end-users perceive treatment costs as a burden.

Companies Mentioned

F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, Teva Pharmaceuticals, Altor BioScience, Amgen, ARIAD Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene, CTI BioPharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, MEDA Pharmaceuticals, MedImmune, Merck, Midas Pharma, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Timeline of development of leukemia drugs
      • Table Impact of key customer segments on market 2015
      • Table Key buying criteria for global leukemia therapeutics market 2015
  • Pipeline portfolio
    • Table Pipeline portfolio: Global CLL therapeutics market
    • Table Pipeline portfolio: Global CML therapeutics market
    • Table Pipeline portfolio: Global ALL therapeutics market
    • Table Pipeline portfolio: Global AML therapeutics market
  • Market landscape
    • Market overview
      • Table Global leukemia therapeutics market snapshot: Developed and emerging markets 2015
    • Market size and forecast
      • Table Distribution of people aged 60 years and over (millions)
      • Table Global leukemia therapeutics market 2015-2020 ($ billions)
      • Table Global leukemia therapeutics market segmentation: Growth cycle analysis
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by disease type
    • Table Segmentation of global leukemia therapeutics market by type of disease 2015
    • Table Global leukemia therapeutics market by type of disease 2015-2020
    • Table Global leukemia therapeutics market segmentation: Growth lifecycle analysis
  • Global CLL therapeutics market
    • Market overview
      • Table Global CLL therapeutics market 2015-2020 ($ billions)
    • Total addressable market for global CLL therapeutics
      • Table Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
    • Vendors in the market
      • Table Major vendors in the CLL therapeutics market 2015
  • Global ALL therapeutics market
    • Market overview
      • Table Global ALL therapeutics market 2015-2020 ($ billions)
    • Vendors in the market
      • Table Major vendors in ALL therapeutics market 2015
  • Global AML therapeutics market
    • Market overview
      • Table Global AML therapeutics market 2015-2020 ($ millions)
    • Vendors in the market
      • Table Major vendors in global AML therapeutics market
  • Global CML therapeutics market
    • Market overview
      • Table Global CML therapeutics market 2015-2020 ($ billions)
    • Vendors in the market
      • Table Major vendors in global CML therapeutics market
  • Geographical segmentation
    • Global leukemia therapeutics market by geography 2015-2020
      • Table Global leukemia therapeutics market by geography 2015-2020
      • Table Percentage share of global leukemia therapeutics market by geography 2015 and 2020
      • Table Global share of leukemia therapeutics market by geography 2015
      • Table Revenue of global leukemia therapeutics market by geography 2015-2020 ($ billions)
      • Table Revenue/growth outlook in different countries/regions 2015
      • Table Global leukemia therapeutics market segmentation by region: Market growth lifecycle analysis 2015
      • Table Leukemia therapeutics market in different regions by type of disease
    • Leukemia therapeutics market in Americas
      • Table Opportunity analysis of leukemia therapeutics market in Americas
      • Table Percentage share of new cases of leukemia in US 2014
      • Table Hispanic population percentage in US total population
      • Table Leukemia therapeutics market in Americas 2015-2020 ($ billions)
    • Leukemia therapeutics market in EMEA
      • Table Opportunity analysis of leukemia therapeutics market in EMEA
      • Table Leukemia therapeutics market in EMEA 2015-2020 ($ billions)
    • Leukemia therapeutics market in APAC
      • Table Opportunity analysis of leukemia therapeutics market in APAC
      • Table Leukemia therapeutics market in APAC 2015-2020 ($ billions)
  • Market drivers
    • Special regulatory designations for drugs
      • Table Orphan designation pipeline drugs for leukemia
      • Table Breakthrough therapy designation drugs for leukemia
    • Technological advances in the monitoring of leukemia
    • Application for expanded indication approvals
      • Table Expanded indication approval drugs in the treatment of leukemia
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Complicated disease prognosis
    • Financial and infrastructural constraints
      • Table Cost of therapy for some leukemia drugs
    • Limitations associated with current therapeutic options
    • Delay in diagnosis
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Rise in the development of combination therapies
      • Table Combination therapies under development for the treatment of leukemia
    • Patient assistance programs
      • Table Leukemia drugs with patient assistance programs
    • Focus on the identification of targets for the development of new therapies
  • Vendor landscape
    • Competitive scenario
      • Table Key vendors ranking 2015
      • Table Geographical presence of key vendors in leukemia therapeutics market 2015
      • Table Competitive landscape of vendors in global leukemia therapeutics market 2015-2020
    • Other prominent vendors
  • Key vendor analysis
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Profile
      • Table F. Hoffmann-La Roche: Strength analysis
      • Table F. Hoffmann-La Roche: Growth strategy matrix
      • Table F. Hoffmann-La Roche: Opportunity assessment
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015
    • Novartis
      • Table Novartis: Profile
      • Table Novartis: Strength analysis
      • Table Novartis: Growth strategy matrix
      • Table Novartis: Opportunity assessment
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Profile
      • Table Bristol-Myers Squibb: Strength analysis
      • Table Bristol-Myers Squibb: Growth strategy matrix
      • Table Bristol-Myers Squibb: Opportunity assessment
    • AbbVie
      • Table AbbVie: Profile
      • Table AbbVie: Strength analysis
      • Table AbbVie: Growth strategy matrix
      • Table AbbVie: Opportunity assessment
    • Teva Pharmaceuticals
      • Table Teva Pharmaceuticals: Profile
      • Table Teva Pharmaceuticals: Strength analysis
      • Table Teva Pharmaceuticals: Growth strategy matrix
      • Table Teva Pharmaceuticals: Opportunity assessment
      • Table Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report